156 related articles for article (PubMed ID: 29520427)
1. The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges.
Akin EA; Kuhl ES; Zeman RK
Abdom Radiol (NY); 2018 Sep; 43(9):2474-2486. PubMed ID: 29520427
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review.
Khessib T; Jha P; Davidzon GA; Iagaru A; Shah J
Semin Nucl Med; 2024 Mar; 54(2):270-292. PubMed ID: 38342655
[TBL] [Abstract][Full Text] [Related]
3. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
4. Present and future of PET and PET/CT in gynaecologic malignancies.
Musto A; Rampin L; Nanni C; Marzola MC; Fanti S; Rubello D
Eur J Radiol; 2011 Apr; 78(1):12-20. PubMed ID: 20116952
[TBL] [Abstract][Full Text] [Related]
5. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma.
Dong Y; Zhang X; Wang S; Chen S; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):438-446. PubMed ID: 25996974
[TBL] [Abstract][Full Text] [Related]
7. PET/CT in gynecologic malignancies.
Brunetti J
Radiol Clin North Am; 2013 Sep; 51(5):895-911. PubMed ID: 24010912
[TBL] [Abstract][Full Text] [Related]
8. Lack of clinical impact of
Liu J; Larcos G; Howle J; Veness M
Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review.
Akin EA; Qazi ZN; Osman M; Zeman RK
Abdom Radiol (NY); 2020 Apr; 45(4):1018-1035. PubMed ID: 32152644
[TBL] [Abstract][Full Text] [Related]
10. PET/MRI in Gynecologic Malignancy.
Larson M; Lovrec P; Sadowski EA; Pirasteh A
Radiol Clin North Am; 2023 Jul; 61(4):713-723. PubMed ID: 37169433
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.
Morkel M; Ellmann A; Warwick J; Simonds H
Int J Gynecol Cancer; 2018 Feb; 28(2):379-384. PubMed ID: 29324535
[TBL] [Abstract][Full Text] [Related]
12. Added Value of FDG PET/MRI in Gynecologic Oncology: A Pictorial Review.
Tarcha Z; Konstantinoff KS; Ince S; Fraum TJ; Sadowski EA; Bhosale PR; Derenoncourt PR; Zulfiqar M; Shetty AS; Ponisio MR; Mhlanga JC; Itani M
Radiographics; 2023 Aug; 43(8):e230006. PubMed ID: 37410624
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET Assessment of Other Gynecologic Cancers.
Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
[TBL] [Abstract][Full Text] [Related]
14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
15. Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.
Gee MS; Atri M; Bandos AI; Mannel RS; Gold MA; Lee SI
Radiology; 2018 Apr; 287(1):176-184. PubMed ID: 29185901
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
17. PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer.
Goel R; Subramaniam RM; Wachsmann JW
PET Clin; 2017 Oct; 12(4):373-391. PubMed ID: 28867110
[TBL] [Abstract][Full Text] [Related]
18. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
19. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
20. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology.
Kim EE
Int J Gynecol Cancer; 2004; 14(1):12-22. PubMed ID: 14764025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
